Junshi Biosciences Back in the Red, Pins Hopes on Covid Drugs
The innovative drug developer reported a first-quarter loss as a result of a steep drop in licensing revenue Key Takeaways: Junshi Biosciences’ revenue tumbled 61% in the first quarter, reflecting…
Recent Articles
RELATED ARTICLES
-
Cancer drug maker Genfleet joins Hong Kong IPO influx
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
- As Covid drug cash dwindles, Vigonvita targets new remedies
-
BeiGene heads for profit milestone after hemorrhaging cash
6160.HK ONC.US 688235.SHG
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
- PegBio aims to bulk up its finances to deliver weight-loss drugs
